Structure/Function vs. Drug Claims

The distinction between Structure/Function claims and Drug claims is a strict and critical regulatory boundary enforced by the fda and ftc in the United States. It governs how supplements, functional beverages, and adult-soft-drinks can be legally marketed.

Definitions

• Structure/Function Claims: Permissible wellness statements and marketing that describe the role of a nutrient or dietary ingredient intended to affect the normal structure or function of the human body.
  • Examples: “May help support a calm mood,” “supports gut health,” or “promotes relaxation.”
• Drug Claims: Impermissible, illegal medical statements for unapproved products that state or imply the product can diagnose, cure, mitigate, treat, or prevent a disease.
  • Examples: “Treats anxiety,” “reduces symptoms of depression,” or “cures insomnia.”

Industry Implications and Compliance Risks

For beverage brands navigating functional-beverage-regulations, crossing the line into drug claims immediately triggers pharmaceutical regulatory pathways that beverage companies are not equipped to navigate. Violating this boundary invites intense regulatory backlash, including warning letters, product seizures, and severe reputational damage.

A specific compliance risk arises when brands use identical branding for both alcoholic and non-alcoholic (NA) variants. Making functional claims on the NA variant that are illegal for the alcoholic counterpart creates significant regulatory exposure and invites immediate scrutiny.

Impact on Valuation and Unit Economics

Functional beverages targeting mood enhancement, stress relief, or medical outcomes operate in a highly scrutinized legal environment. Navigating this boundary requires extensive independent clinical testing and legal review, which adds substantial regulatory compliance costs to a brand’s operational overhead.

However, successfully managing this distinction is critical for venture capital and M&A outcomes. Brands that successfully bridge the clinical-substantiation-gap, secure defensible IP, and establish validated, compliant structure/function claims command significantly higher valuations from strategic acquirers.